Moexipril Hydrochloride NDC 68462-209

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-209Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0209Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
68462-209-01	68462020901	100 TABLET, FILM COATED in 1 BOTTLE (68462-209-01)Marketed from Dec 31, 2010
68462-209-10	68462020910	1000 TABLET, FILM COATED in 1 BOTTLE (68462-209-10)Marketed from Dec 31, 2010
68462-209-90	68462020990	90 TABLET, FILM COATED in 1 BOTTLE (68462-209-90)Marketed from Dec 31, 2010

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Moexipril Hydrochloride
Generic name (nonproprietary): moexipril hydrochloride
Active ingredients: Moexipril hydrochloride — 7.5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090416
Marketing start: Dec 31, 2010
Listing expires: Dec 31, 2027
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)
Identifiers: Product ID 68462-209_66bb1c8f-1f66-4834-86a3-a387d076aa22SPL ID 66bb1c8f-1f66-4834-86a3-a387d076aa22SPL set ID baac91ad-f8ee-4694-89f8-5c47a8eda39aRxCUI 1299896, 1299897UNII Q1UMG3UH45UPC 0368462209011, 0368462208014
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468462020901 followed by a unit qualifier and the quantity

Package 68462-0209-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. They may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride tablets do not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black pa…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090416

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090416
Product	Strength	Form · route	Labeler	Product NDC
Moexipril Hydrochloride	Moexipril hydrochloride 15 mg/1	Tablet, Film coatedOral	Glenmark Pharmaceuticals Inc., USA	68462-208